TQB3616

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Breast CancerInteraction

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

1

TQB3616

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

62

Adenocard

Astellas

Preclinical

23

Lexiscan

Astellas

Preclinical

14

Blenoxane

Bristol-Myers Squibb

Preclinical

15

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

16

Nubain

AAultman Health Foundation

Preclinical

17

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

18

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

19

Ablavar

LLantheus Medical Imaging

Preclinical

210

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

1Show 20 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Breast Cancer6 trials

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

Active, not recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT05365178·432 enrolled

TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

Active, not recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT05375461·287 enrolled

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

Recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1/2·NCT06202261·154 enrolled

Show 3 more trials

A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT04796623·120 enrolled

Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

Recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT05780567·1,946 enrolled

Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Not yet recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT06702618·33 enrolled

Dedifferentiated Liposarcoma1 trial

TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma

Terminated·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT05496569·26 enrolled

Lung Cancer1 trial

A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT04924192·126 enrolled

Clinical Trial1 trial

Clinical Trial for Effect of TQB3616 Capsule on Pharmacokinetics in Healthy Adult Subjects

Completed·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT05344729·16 enrolled

Interaction1 trial

Drug-Drug Interaction (DDI) Study for TQB3616

Not yet recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT06662773·40 enrolled

2 more indications

Tolerance1 trial

A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT03850873·30 enrolled

Unspecified1 trial

Mass Balance Study of TQB3616

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT06149611·8 enrolled

Details

Drug Info

Related News